AHR and breast carcinoma: In the present study, the clinical relevance of our in vitro findings was further reinforced by retrospective analysis of two independent breast cancer cohorts, showing that in only ER-negative or triple-negative breast cancer subclasses, the gene signature involving both AhR and GPR30 mRNA levels were of poor prognosis.